NCT04831879 (AMBITION) is a NA clinical trial of GONDOLA AMPS in Parkinson Disease, sponsored by Gondola Medical Technologies SA.

Who is sponsoring NCT04831879?

NCT04831879 is sponsored by Gondola Medical Technologies SA.

What drugs are being tested in NCT04831879?

Interventions in NCT04831879: GONDOLA AMPS.

What condition does NCT04831879 study?

NCT04831879 studies Parkinson Disease, Gait Disorders, Neurologic.

Is NCT04831879 still recruiting?

NCT04831879 is currently status unknown. Last updated 15 April 2021.

Last reviewed 2021-04-15 · How we verify

NCT04831879: AMBITION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Automated Mechanical Peripheral Stimulation to Treat Freezing of Gait in Patients With Parkinson's Disease and STN-DBS

Status unknown NA Last updated 15 April 2021

What this trial tests

NA trial testing GONDOLA AMPS in Parkinson Disease in 40 participants. Status unknown.

Timeline

25 March 2021

Primary endpoint
27 April 2022

30 June 2022

Quick facts

Lead sponsor	Gondola Medical Technologies SA
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	40
Start date	25 March 2021
Primary completion	27 April 2022
Estimated completion	30 June 2022
Sites	1 location across Germany

Drugs / interventions tested

GONDOLA AMPS

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →
Gait Disorders, Neurologic — all drugs for Gait Disorders, Neurologic →

Sponsor

Gondola Medical Technologies SA

Who can join

18 and older, any sex, with Parkinson Disease or Gait Disorders, Neurologic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to investigate whether AMPS (Automated Mechanical Peripheral Stimulation) is effective in reduction of FOG measured via the FOG-AC (Freezing Of Gait Assessment Course) in people with Parkinson Disease and STN-DBS (Subthalamic Nucleus Deep Brain Stimulation) in a randomized, double-blind, sham-controlled, cross-over trial

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04831879 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gondola Medical Technologies SA
Last refreshed: 15 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04831879.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing